Conference Coverage

New data underscore importance of biologic ‘sweet spot’


 

EXPERT ANALYSIS FROM 2015 ADVANCES IN IBD

References

But just what length of time actually constitutes “immediately after surgery?” In the PREVENT trial, clinicians had up to 45 days to begin therapy, although Dr. Regueiro said he prefers to start between 2 and 4 weeks postsurgery, a number with which panel moderator Dr. David T. Rubin, codirector of the University of Chicago Digestive Diseases Center, agreed.

While these study results help pinpoint the range for when to use biologics, Dr. Regueiro said in the interview, “Future study is need to determine the ‘tipping point’ where postoperative Crohn’s disease recurrence results in significant bowel damage and renders medications ineffective. Finding the ‘biologic sweet spot’ of when to start aggressive therapy versus a ‘wait and watch’ approach remains the question.”

Dr. Regueiro disclosed he is a consultant for AbbVie, Janssen, UCB, Pfizer, and Takeda.

wmcknight@frontlinemedcom.com

On Twitter @whitneymcknight

Pages

Recommended Reading

Measure found significant variations in outpatient colonoscopy quality
MDedge Internal Medicine
PPIs caused remission in about half of esophageal eosinophilia cases
MDedge Internal Medicine
Nonalcoholic fatty liver disease linked to liver cancer without cirrhosis
MDedge Internal Medicine
Hepatitis C virus infection linked to cardiovascular death, disease, and stroke
MDedge Internal Medicine
New regimen for hepatitis C genotype 2 beats previous standard of care
MDedge Internal Medicine
Treatment failure reduced in Barrett’s esophagus with endoscopic mucosal resection
MDedge Internal Medicine
Tricks for treating C. diff in IBD
MDedge Internal Medicine
Physicians need to be more proactive in learning about patient IBS symptoms
MDedge Internal Medicine
Jury still out on appendectomy vs. antibiotics-first approach
MDedge Internal Medicine
Nonalcoholic fatty liver disease will keep rising ‘in near term’
MDedge Internal Medicine